Hormone Receptor-Positive Breast Cancer
This track examines updates in endocrine therapies, resistance mechanisms, and combination strategies for ER/PR-positive breast cancer. Learn about next-generation SERDs, CDK4/6 inhibitors, and how genomic profiling is refining hormone-driven treatment planning. Patient management and long-term survivorship challenges will also be covered.